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BACKGROUND: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the
development of adenocarcinoma. To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we
characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer.
METHODS: Tissue microarrays were constructed from tumour samples from 54 patients with all stages of the disease.
Immunohistochemistry and microsatellite instability (MSI) testing were conducted.
RESULTS: The profile of cytokeratin 20 and 7 coexpression was variable, but expression of caudal type homeobox transcription
factor 2 (CDX2) was present in 70% of cases. In this young population (median age 54 years), loss of mismatch repair (MMR)
proteins occurred in 35% of patients, with confirmed MSI in 100% of tested cases. Expression of vascular endothelial growth factor-A
(VEGF-A) and epidermal growth factor receptor (EGFR) was common, occurring in 96 and 71% of patients, respectively. Only one
case showed HER2 expression and none showed loss of phosphatase and tensin homologue mutated on chromosome 10 (PTEN).
CONCLUSIONS: These results suggest that alterations in DNA MMR pathways are common in SBAs, similar to what is observed in large
bowel adenocarcinomas. Furthermore, the high percentage of tumours expressing both EGFR and VEGF suggests that patients with
this rare cancer may benefit from therapeutic strategies targeting EGFR and VEGF receptor (VEGFR).
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Adenocarcinoma of the small bowel is a rare, aggressive
malignancy with poor overall outcome. The majority of patients
with small bowel adenocarcinoma (SBA) present with advanced
disease, with 5-year disease-specific survival rates of 35% for
patients with lymph node involvement and 4% for patients with
metastatic disease (Howe et al, 1999). Although the small intestine
makes up approximately 75% of the length and 90% of the mucosal
surface of the gastrointestinal tract, SBA occurs 50 times less
frequently than colorectal adenocarcinoma (O’Riordan et al, 1996;
DeSesso and Jacobson, 2001). Despite this intriguing biological
difference in the incidence of SBA and colorectal adenocarcinoma,
few investigations into the mechanisms of small bowel carcino-
genesis have been conducted. A number of theories have been
postulated to explain the relative protection of the small intestine
from the development of carcinoma; however, none have been
proven. Proposed protective factors have generally centred around
two concepts. First, the rapid turnover of small intestinal cells
results in epithelial cell shedding before the accumulation of the
genetic damage critical to carcinogenesis. Second, exposure of the
small intestine to the carcinogenic components of our diet is
limited because of the small intestine’s rapid transit time, lack of
bacterial degradation activity, and relatively dilute alkaline
environment.
As in colorectal cancer, a subset of SBAs are characterised by a
defect in DNA mismatch repair (MMR), which results in DNA
microsatellite instability (MSI) (Planck et al, 2003). Microsatellite
instability is characterised by the accumulation of changes in
the length of simple repeated nucleotide sequences known as
microsatellites, caused by mutations in MMR genes such as MutS
homologue 2 (hMSH2), MutL homologue 1 (hMLH1), post meiotic
segregation increased 1 (hPMS1), hPMS2, and hMSH6. Although
MSI is a hallmark of hereditary nonpolyposis colorectal cancer
syndrome, in which mutations of one or more MMR genes are
found in 490% of the cases, it has also been reported in
approximately 10% of sporadic colorectal adenocarcinomas (Liu
et al, 1995). In colorectal cancer, defects in DNA MMR are
characterised by a younger age of onset, poorly differentiated
mucinous tumours, and improved outcomes (Gryfe et al, 2000;
Jenkins et al, 2007). However, for patients with SBA, no
comprehensive study has been conducted to compare the clinical
and pathological differences between patients with intact and
deficient DNA MMR.
Other oncogenic signalling pathways that are active in colorectal
cancer include the epidermal growth factor receptor (EGFR),
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svascular endothelial growth factor receptor (VEGFR), and
phosphatidylinositol 3-kinase (PI3K)/AKT pathways. Epidermal
growth factor receptor is a member of the ErbB family of
transmembrane receptor tyrosine kinases that have a crucial role
in tumour cell proliferation, survival, adhesion, migration, and
differentiation (Yarden and Sliwkowski, 2001). Although the
expression of EGFR has not been evaluated in SBA, one study
has evaluated the expression of the ErbB family member, HER2. In
this study, 9 of 16 patients showed HER2 expression and such
expression was associated with a worse overall survival (OS; Zhu
et al, 1996). Vascular endothelial growth factor signalling has a key
role in tumour-associated neo-angiogenesis and the PI3K/AKT
pathway is a critical pro-survival and pro-proliferation pathway
that is frequently activated in a variety of cancers (Stambolic et al,
1998). The phosphatase and tensin homologue mutated on
chromosome 10 (PTEN) protein acts as a potent tumour
suppressor of this pathway and loss of PTEN expression is
observed in approximately 5% of colorectal cancer (Zhou et al,
2002; Goel et al, 2004). Currently, no studies have evaluated the
expression of EGFR, VEGF-A, or PTEN in SBA.
In addition, the published data on the immunophenotype of
SBA are limited and conflicting (Lee et al, 2003; Chen and Wang,
2004). To date, no study has evaluated the expression of caudal
type homeobox transcription factor 2 (CDX2) in a large number of
patients with SBA. It is critical for the development and
differentiation of the intestines, and highly expressed in cancers
of the large intestine (Moskaluk et al, 2003; Werling et al, 2003).
To characterise the immunophenotype and the expression of a
number of candidate oncogenic proteins, we performed immuno-
histochemical analysis of tumour samples from a large data set of
SBA patients treated at The University of Texas M.D. Anderson
Cancer Center. As a number of the proteins analysed represent
therapeutic targets for drugs currently in clinical use, the results of
this study have direct clinical relevance for the potential treatment
of this rare cancer.
MATERIALS AND METHODS
Study population and tumour samples
We searched the M.D. Anderson Cancer Center pathology database
from 1981 to 2007 for cases of SBA with accompanying pathologic
materials. A total of 83 cases were identified and 54 cases were
included. In all, 23 cases with inadequate pathologic materials and
six cases of ampullary adenocarcinoma were excluded. The
haematoxylin and eosin (H&E)-stained slides from all 54 cases
were reviewed by a gastrointestinal pathologist (HW) to confirm
the diagnosis and tumour grades. Normal small bowel mucosa
samples were present in all but 12 of the cases. We retrospectively
collected clinical and follow-up data, including demographics,
cancer treatment history, stage, and survival for each patient from
patient records. Tumour samples were from the primary site of
resection in 43 cases and from a metastatic site in 11 cases. A total
of 10 patients received anticancer therapy before collection of the
pathologic material, with therapy consisting of chemoradiation in
three cases and systemic chemotherapy in seven cases.
This study was carried out in accordance with the guidelines of
the institutional review board.
Tissue microarray
To construct the tissue microarray, the formalin-fixed, paraffin-
embedded archival tissue blocks and their matching H&E-stained
slides were retrieved, reviewed, and screened for representative
tumour regions and normal small bowel mucosa by a gastro-
intestinal pathologist (HW). For each patient, three cores of
tumour and when available, two cores of paired normal small
bowel mucosa, were sampled from representative areas using a
1.0-mm punch. The tissue microarray was constructed with a
tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA)
as described previously (Wang et al, 2002). The constructed TMA
blocks were sealed with paraffin, and 5-mm-thick slides were cut
from the TMA blocks for immunohistochemical staining.
Immunohistochemistry
Immunohistochemical stains were performed on 5mm unstained
sections from the tissue microarray blocks using the antibodies
listed in Table 1. To retrieve the antigenicity, the tissue sections
were treated at 1001C in a steamer containing 10mmol citrate
buffer (pH 6.0) for 60min. The sections were then immersed in
methanol containing 0.3% hydrogen peroxidase for 20min to
block the endogenous peroxidase activity and were incubated in
2.5% blocking serum to reduce nonspecific binding. Sections were
incubated for 90min at 371C with primary antibodies at the
dilutions specified in Table 1. Standard avidin–biotin immuno-
histochemical analysis of the sections was performed according
to the manufacturer’s recommendations (Vector Laboratories,
Burlingame, CA, USA). Diaminobenzidine tetrahydrochloride was
used as a chromogen, and haematoxylin was used for counter-
staining.
Two observers independently analysed the immunostaining
results and their intensities (JVP and HW). Positive and negative
controls were used for each antibody on each slide. A third
investigator (MJO) re-evaluated any cases with discrepancies
between the two interpretations. Expression of PTEN, PMS2,
hMLH-1, hMSH-2, hMSH-6, CK20, CK7, and CDX2 was considered
positive if 410% of the tumour cells show immunoreactivity.
Table 1 Antibodies used
Antibody Clone Titre Company
Anti-CDX2 CDX-88 1:50 Biogenex, San Ramon, CA, USA
Anti-CK7 OVT-TL 12/30 1:100 Dako, Carpinteria, CA, USA
Anti-CK20 KS20.8 1:4000 Dako, Carpinteria, CA, USA
Anti-EGFR 31G7 1:50 Invitrogen, Inc., Carlsbad, CA, USA
Anti-HER2 neu Ab8 1:300 Labvision, Inc., Fremont, CA, USA
Anti-MLH-1 G168-15 1:25 BD Biosciences, San Jose, CA, USA
Anti-MSH-2 FE11 1:100 Calbiochem, Inc., Gibbstown, NJ, USA
Anti-MSH-6 44 1:300 BD Biosciences, San Jose, CA, USA
Anti-PMS2 A16-4 1:125 BD Biosciences, San Jose, CA, USA
Anti-PTEN 28H6 1:100 Novacastra, Bannockburn, IL, USA
Anti-VEGF-A VEGF A20 1:10 Santa Cruz Biotechnology, Santa Cruz, CA, USA
Abbreviations: CDX2¼caudal type homeobox transcription factor 2; EGFR¼epidermal growth factor receptor; MLH-1¼MutL homologue 1; MSH-2¼MutS homologue 2;
PMS2¼post meiotic segregation increased 2; PTEN¼phosphatase and tensin homologue mutated on chromosome 10; VEGF-A¼vascular endothelial growth factor A.
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HER2 testing in breast cancer with 2þ or 3þ membranous
staining in 10% of the tumour cells as positive (Wolff et al, 2007).
For VEGF-A and EGFR, both the percentage of positive tumour
cells and the intensity of positive staining were graded. The
percentage of staining was graded as follows: 0, staining in o1% of
tumour cells; 1, staining in 1–20% of tumour cells; 2, staining in
20–50% of tumour cells; and 3, staining in 50–100% of tumour
cells. The intensity of staining was graded as follows: 0, no staining;
1, weak staining; 2, moderate staining; and 3, strong staining.
Composite grades for EGFR and VEGF-A was generated on a scale
of 0–6 by adding grade for the percentage of cells stained to the
grade for staining intensity (Goldstein and Armin, 2001).
Microsatellite analysis
Representative slides from tumour and normal small bowel
mucosa were obtained for each case and macro-dissection of the
relevant tissue was performed. DNA was extracted by proteinase K
digestion (Mirabelli-Primdahl et al, 1999). Genomic DNA was
amplified by polymerase chain reaction (PCR) using fluorescently
labeled and unlabeled primers for each of the five National Cancer
Institute-recommended microsatellite markers (BAT-25, BAT-26,
D2S123, D5S346, and D17S250). Polymerase chain reaction
products were electrophoretically separated using an ABI 3130
analyser (Applied Biosystems, Foster City, CA, USA) and analysed
using GeneMapper 4.0 software (Applied Biosystems). Samples
with MSI at two or more loci were classified as MSI high, whereas
samples with MSI at either one or none of the loci were classified
as MSI low or microsatellite stable (MSS), respectively (Umar
et al, 2004).
Statistical analysis
Fisher’s exact test was used to assess the association between
various molecular markers. Overall survival curves were
constructed using the Kaplan–Meier method, and the log-rank
test was used to evaluate the statistical significance of differences
and association with each molecular marker. The Cox proportional
hazards regression model was used to assess the predictive effects
of multiple covariates (including histology, stage, biomarkers, and
demographical variables of the patients) on OS simultaneously. All
analyses were performed using the S-PLUS software package
(TIBCO Software Inc., Palo Alto, CA, USA).
RESULTS
Clinicopathological characteristics of patients with SBA
The patient and tumour characteristics are summarised in Table 2.
The ages of the patients ranged from 30 to 79 years, with a median
of 54 years. The primary tumour site in the small bowel was the
duodenum in 74% of cases.
Immunophenotype of SBA
The most commonly expressed immunophenotypic marker was
CDX2, observed in 38 patients (70%). The expression of CDX2
varied according to histological grade, with 100% of well-
differentiated tumours and 58% of poorly differentiated tumours
expressing CDX2. Expression of CK20 occurred in 31 (57%)
patients, and expression of CK7 occurred in 17 (31%) patients. The
most common combined cytokeratin expression pattern was
CK20þ/CK7  observed in 23 (43%) patients, followed by
CK20 /CK7  observed in 15 (28%) patients (Table 3). There
was no significant difference in the expression of CK7, CK20, and
CDX2 between the duodenal and nonduodenal SBA or between the
primary and metastatic tissue sites.
Expression of DNA MMR enzymes and microsatellite
instability
A total of 18 cases (35%) of SBA showed loss of expression of at
least one MMR protein by immunohistochemical stains (Figure 1A
and B). In all, three (6%) patients showed loss of MSH-2, six (11%)
showed loss of MSH-6, 13 (24%) showed loss of PMS2, and 14
(26%) showed loss of hMLH-1. Loss of MMR protein expression
generally occurred in two patterns, with combined loss of
either MSH-2 with MSH-6 or PMS2 with hMLH-1. Because of the
large number of patients who showed loss of MMR protein
expression, we confirmed these results with MSI testing for these
18 cases. MSI testing was successful in 15 cases but could not be
conducted in three cases because of lack of normal control tissue
in two cases and lack of residual tumour tissue in one case. One
case had an MSI-low phenotype and 14 cases had an MSI-high
phenotype. Of the 15 cases showing MSI, 69% of the patients
were younger than 55 years at the time of initial diagnosis.
A comparison of patient and tumour characteristics between
patients with intact MMR and patients with deficient MMR is
presented in Table 4. Patients with deficient MMR tended to be
younger and had a lower frequency of distant metastasis at
presentation. As is observed in MMR-deficient adenocarcinomas
of the colon, SBA with deficient MMR showed a significant lower
frequency of CK20 expression than SBA with intact MMR (Table 4,
P¼0.02) (McGregor et al, 2004).
Expression of VEGF-A, EGFR, HER2, and PTEN
Expression of VEGF-A, score 2–6, was observed in 50 (91%)
patients and expression of EGFR, score 2–6, was observed in 36
(71%) patients (Figure 1C and D). The majority of cases showed
high levels of expression with a score of 4–6 observed in 44 (81%)
patients with VEGF-A and 26 (48%) patients with EGFR.
Table 2 Patient and tumour characteristics
Characteristic No. (%) of patients
Age
Median 54years
Range 30–79years
Sex
Men 34 (63)
Women 20 (37)
Ethnicity
Caucasian 43 (80)
Black 5 (9)
Other 6 (11)
Initial stage
I 5 (9)
II 11 (20)
III 23 (43)
IV 15 (28)
Primary tumour site
Duodenum 40 (74)
Jejunum 4 (7)
Ileum 8 (15)
Small bowel NOS 2 (4)
Mucinous histology 15 (28)
Histological grade
Well differentiated 4 (8)
Moderately differentiated 38 (70)
Poorly differentiated 12 (22)
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patients showed loss of PTEN expression.
Survival analysis
The median follow-up time was 45 months and the median
survival was 46 months (95% CI 38–167 months). In the univariate
analysis, TNM classification and VEGF-A expression correlated
with OS (Figure 2A and B). Patients with low expression of
VEGF-A (score of 0 or 1) had a shorter median OS, 19.9 months,
compared with patients with high expression of VEGF-A, 74.8
months, P¼0.027. The group of patients with low expression of
VEGF-A also had a higher rate of metastatic disease (63% of
patients) than patients with high VEGF-A expression (22% of
patients), P¼0.035. There was no difference in outcome by EGFR
expression level or MMR protein expression status. On multi-
variate survival analysis, patients with higher TNM stage (hazard
ratio (HR) 3.15, P¼0.002) and poorly differentiated tumours (HR
2.95, P¼0.049) showed significantly shorter OS.
DISCUSSION
Our study represents one of the largest clinicopathological studies
of SBA and provides a clinically needed, robust immunopheno-
typic characterisation of this rare cancer as well as an exploration
of the role of various oncogenic pathways in this tumour type. As
in colorectal cancer, expression of CDX2, VEGF-A, and EGFR was
observed in the majority of cases, but HER2/neu expression and
loss of PTEN expression are rare oncogenic abnormalities in this
cancer. Abnormalities in DNA MMR were common, occurring in
over one-quarter of patients, but did not correlate with OS. In
multivariate analysis, higher TNM stage and poorly differentiated
histology were correlated with worse OS.
The expression pattern of cytokeratins, particularly CK20 and
CK7, has proven clinical utility in determining the site of epithelial
origin for various carcinomas. For colorectal cancer, a CK20þ/
CK7  expression pattern is observed in 75–94% of all patients
(Loy et al, 1996; Rullier et al, 2000). In two previous large series of
SBA, which included 23 (Lee et al, 2003) and 24 (Chen and Wang,
2004) patients, the reported rate of CK7 expression was 34 and
100%, respectively, and the rate of CK20 expression was 47 and
67%, respectively. Our study shows a low rate of CK7 expression in
SBA patients, with the classic CK20þ/CK7  colorectal cancer
expression pattern observed in only 43% of patients. More
clinically relevant was the high rate of CDX2 expression observed
in this population (70%). This is similar to a previous report in
which CDX2 positivity was observed in 4 out of 4 cases of
adenocarcinoma of the duodenum and 18 of 30 cases of SBA
(Werling et al, 2003; Zhang et al, 2007). The CDX2 is a highly
sensitive marker for identifying adenocarcinomas of colonic
origin, with expression observed in over 95% of colorectal cancers
(Moskaluk et al, 2003; Werling et al, 2003). Colorectal cancer cases
that are negative for CDX2 expression tend to be poorly
differentiated tumours, and consistent with this finding, we
observed that whereas 100% of well-differentiated tumours were
Table 3 Number of patients with each immunophenotype
CDX2 CK20 CK7 CK20+/CK7  CK20þ/CK7þ CK20 /CK7  CK20 /CK7þ
Positive, % 70 57 31 43 15 28 13
Negative, % 30 43 69 57 85 72 87
hMLH1 negative AB
CD
hMLH1 positive
EGFR VEGF
Figure 1 Representative immunohistochemical staining (original magnification  100) of (A) absent MLH1 expression; (B) intact MLH1 expression;
(C) epidermal growth factor receptor (EGFR) expression; and (D) vascular endothelial growth factor (VEGF) expression.
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CDX2 positive (Werling et al, 2003).
The reported incidence of abnormalities in MMR genes in SBA
patients has been variable, ranging from 5 to 45% by microsatellite
testing and from 0 to 26% by immunohistochemical staining of
tumour samples (Hibi et al, 1995; Rashid and Hamilton, 1997;
Blaker et al, 2002; Planck et al, 2003; Brueckl et al, 2004; Zhang
et al, 2006). In our study, we saw a higher rate of defective MMR,
with 35% of patients showing loss of MMR protein expression.
This high rate was confirmed by MSI PCR analysis in all cases with
available tissue. The high incidence of MSI in this study may
relate with the young age of our study population. As in MSI
colorectal cancer, SBA patients with MSI tended to be younger,
have earlier-stage disease, and have a lower rate of CK20
expression (Gryfe et al, 2000; McGregor et al, 2004). In contrast
with colorectal cancer, we did not see any evidence of an improved
prognosis in the subset of patients with deficient expression of
MMR proteins.
In an attempt to identify other oncogenic pathways involved in
SBA, we characterised two members of the ErbB receptor tyrosine
kinase family (EGFR and HER2), the pro-angiogenic protein
VEGF-A, and the tumour suppressor protein PTEN. In one study
of duodenal adenocarcinoma, HER2 was expressed in 9 of 16 cases
and expression was correlated with a worse outcome (Zhu et al,
1996). In contrast, our study found HER2 expression in only 1 of
54 cases. The explanation for this discrepancy is unclear, although
lack of specificity with the antibody used by Zhu et al. (1996) may
be one explanation. The expression of EGFR was present in 71% of
cases, which is similar to the rate of expression observed in
colorectal cancer. As in colorectal cancer, the expression level of
EGFR was not associated with changes in survival (McKay et al,
2002). Although limited numbers of patients have been tested, it
seems that activating mutations in the KRAS oncogene are
observed in approximately 40% of SBA patients, which is similar
to the rate observed in colorectal cancer (Bamford et al, 2004).
This finding, in conjunction with our finding of the high rate of
EGFR expression in SBA, supports the clinical investigation of
anti-EGFR therapy for SBA patients, with particular emphasis on
patients without activating mutations in the KRAS oncogene.
We saw expression of VEGF in 91% of patients with SBA. This
correlates with another study that found universal expression of
VEGF-A RNA in a small number of SBA patients (von Rahden
et al, 2006). Interestingly, our data showed worse survival in those
patients with low levels of VEGF-A expression. This subgroup of
patients had a much higher rate of metastatic disease, which may
suggest the presence of alternative pro-invasion and pro-meta-
static signalling pathways. Fibroblast growth factor, platelet-
derived growth factor, and notch-mediated signalling are all
examples of pro-angiogenic stimuli that are not dependant on
VEGF ligand expression (Ellis and Hicklin, 2008). The importance
of alternative angiogenic pathways has recently been shown by
work in mouse model systems, in which greater invasiveness and
higher rates of distant metastases were observed after the genetic
ablation of the VEGF-A gene (Paez-Ribes et al, 2009). Given the
limited sample size of this study, further investigation to verify the
effect of the VEGF pathway on the outcome in small bowel
adenocarcinoma is needed.
Table 4 Patient and tumour characteristics stratified by intact or
deficient DNA mismatch repair (MMR) status
Number of patients (%)
Intact MMR Deficient MMR P-value
Patient number 36 18
Age 0.63
Median 56 49
Range 30–78 37–79
Sex 0.99
Men 23 (64) 11 (61)
Women 13 (36) 7 (39)
Stage 0.5
I 4 (11) 1 (6)
II 7 (19) 4 (22)
III 13 (36) 10 (56)
IV 12 (33) 3 (17)
Primary tumour site 0.3
Duodenum 27 (75) 13 (72)
Jejunum 4 (11) 4 (22)
Ileum 4 (11) 0 (0)
Small bowel NOS 1 (3) 1 (6)
Mucinous histology 9 (25) 6 (33) 0.54
Histological grade 0.18
Well differentiated 2 (6) 2 (11)
Moderately differentiated 19 (53) 13 (72)
Poorly differentiated 9 (25) 3 (17)
CK 20 expression 25 (69) 6 (33) 0.02
CK 7 expression 11 (31) 6 (33) 0.99
CDX-2 expression 26 (72) 12 (67) 0.76
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Figure 2 Kaplan–Meier overall survival plots according to (A) TNM
classification and (B) expression of vascular endothelial growth factor A
(VEGF-A), expression score 0–2 vs 3–6.
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some 10 is a potent tumour suppressor that is commonly lost in a
number of sporadic tumours and inherited loss of PTEN results in
Cowden’s syndrome. This syndrome is characterised by multiple
hamartomas that occur throughout the gastrointestinal tract,
including the small bowel. In mouse models, the loss of PTEN in
the context of APC deficiency accelerates tumourigenesis through
increased activation of AKT, leading to the rapid development of
adenocarcinoma (Dahia, 2000). In colorectal cancer, inactivation
of PTEN is primarily observed in patients with MSI tumours,
occurring in 14–19% of cases (Zhou et al, 2002; Goel et al, 2004).
We did not identify any patients with loss of PTEN expression,
which may suggest a less critical role for the PI3K/AKT pathway in
carcinogenesis in the small bowel. Similarly, as the majority of
PTEN inactivation in colorectal cancer results from pten gene
methylation, this result may suggest a more limited role of
hypermethylation in SBA compared with colorectal cancer.
In summary, this study characterised the immunophenotype,
DNA MMR gene status and the expression of a number of
candidate oncogenic proteins in a large group of SBA. The high
levels of VEGF-A and EGFR expression in SBA provide a rationale
for the exploration of therapies targeting these oncogenic pathways
in this rare tumour type.
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